Quick Answer
Immuneering Corp reported Total Revenue of $0.00 for fiscal year 2023.
Immuneering Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $0.00 -100.0% |
$317.0K -84.8% |
$2.08M -10.0% |
$2.31M |
| Net Income | -$56.02M +8.2% |
-$61.04M -14.1% |
-$53.47M -5.9% |
-$50.51M -50.6% |
-$33.54M -96.8% |
-$17.04M |
| Diluted EPS | -$1.27 +37.7% |
-$2.04 -8.5% |
-$1.88 +1.6% |
-$1.91 +22.4% |
-$2.46 +28.5% |
-$3.44 |
| Total Assets | $231.99M +340.1% |
$52.71M -48.6% |
$102.58M -16.2% |
$122.37M -26.6% |
$166.70M +333.9% |
$38.42M |
| Cash and Equivalents | $128.65M +255.9% |
$36.14M -39.2% |
$59.41M -18.2% |
$72.64M -3.0% |
$74.89M +101.9% |
$37.09M |
| Stockholders Equity | $218.48M +427.9% |
$41.39M -54.3% |
$90.58M -17.5% |
$109.85M -29.6% |
$155.98M +793.8% |
-$22.48M -244.4% |
| R&D Expense | $42.05M -12.3% |
$47.96M +15.2% |
$41.62M +14.8% |
$36.27M +36.6% |
$26.54M +76.9% |
$15.00M |
| Operating Income | -$59.38M +7.3% |
-$64.07M -9.7% |
-$58.41M -12.9% |
-$51.74M -52.7% |
-$33.89M -98.4% |
-$17.08M |
| Gross Profit | — | — | $0.00 -100.0% |
$158.8K -82.9% |
$926.9K -10.1% |
$1.03M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2023 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$14.96M | -2.5% | -3.7% |
| Diluted EPS | September 30, 2025 | -$0.38 | +22.4% | +5.0% |
| Total Assets | September 30, 2025 | $241.06M | — | +501.8% |
| Cash and Equivalents | September 30, 2025 | $227.56M | — | +763.4% |
| Stockholders Equity | September 30, 2025 | $227.98M | +295.0% | +687.9% |
| R&D Expense | September 30, 2025 | $10.87M | -3.4% | +4.0% |
| Operating Income | September 30, 2025 | -$15.38M | -0.7% | -4.2% |
| Gross Profit | September 30, 2023 | $0.00 | -100.0% | — |
- Immuneering Corp reported Total Revenue of $0.00 for fiscal year 2023.
- Immuneering Corp showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Immuneering Corp reported Net Income of -$56.02 million for fiscal year 2025.
- Immuneering Corp showed an increase of +8.2% in Net Income compared to the prior fiscal year.
- Immuneering Corp reported Diluted EPS of $1.27 per share (loss) for fiscal year 2025.
- Immuneering Corp showed an increase of +37.7% in Diluted EPS compared to the prior fiscal year.
- Immuneering Corp reported Total Assets of $231.99 million for fiscal year 2025.
- Immuneering Corp showed an increase of +340.1% in Total Assets compared to the prior fiscal year.
- Immuneering Corp reported Cash and Equivalents of $128.65 million for fiscal year 2025.
- Immuneering Corp showed an increase of +255.9% in Cash and Equivalents compared to the prior fiscal year.
- Immuneering Corp reported Stockholders Equity of $218.48 million for fiscal year 2025.
- Immuneering Corp showed an increase of +427.9% in Stockholders Equity compared to the prior fiscal year.
- Immuneering Corp reported R&D Expense of $42.05 million for fiscal year 2025.
- Immuneering Corp showed a decrease of -12.3% in R&D Expense compared to the prior fiscal year.
- Immuneering Corp reported Operating Income of -$59.38 million for fiscal year 2025.
- Immuneering Corp showed an increase of +7.3% in Operating Income compared to the prior fiscal year.
- Immuneering Corp reported Gross Profit of $0.00 for fiscal year 2023.
- Immuneering Corp showed a decrease of -100.0% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: